Pitfalls in retrospective analyses of biomarkers: A case study with metastatic melanoma patients

Journal of Immunological Methods

Volumn 376, Issue 1-2, 2012, Pages 108-112

  Potter, Douglas M ^a,b   Butterfield, Lisa H ^a   Divito, Sherrie J ^a   Sander, Cindy A ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bias; Biomarker; Metastatic melanoma; Retrospective; Survival

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; EOTAXIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CASE STUDY; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TUMOR; SUBCUTANEOUS TISSUE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856520594     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.12.003     Document Type: Article

References (11)

1. American Cancer Society Cancer facts and figures 2006. http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf.
2. Balch C.M. Cancer: Principles and Practice of Oncology 1997, Lippencott, Philadelphia. 5 ed.
3. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001, 19:3622.
4. Butterfield L.H., Potter D.M., Kirkwood J.M. Technical and biostatistical issues in multiplex serum biomarker assessments. J. Transl. Med. 2011, 9:173.
5. De Jager W., Bourcier K., Rijkers G.T., et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol. 2009, 10:52.
6. Gorelik E., Landsittel D.P., Marrangoni A.M., et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14:981.
7. Kim C.J., Reintgen D.S., Balch C.M. The new melanoma staging system. Cancer Control 2002, 9:9.
8. Korn E.L., Liu P.Y., Lee S.J., et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 2008, 26:527.
9. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: reporting recommendations for tumor marker prognostic studies, JNCI 2005 97:1180.
10. Omenn G.S., Goodman G., Thornquist M., et al. The β-Carotene and Retinol Efficacy Trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Can. Res. Suppl. 1994, 54:2048s.
11. Thompson J.F., Scolyer R.A., Kefford R.F. Cutaneous melanoma. Lancet 2005, 365:687.